News | September 03, 2023
BioNTech to lead $2 billion mRNA-based oncology therapy market despite challenges, says GlobalData
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million
Ryan has nearly 20 years of global legal and IP expertise in the pharmaceutical industry
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
The programme was conducted as a part of MPMCx, an exclusive management programme for MBBS doctors by IIM-Ahmedabad in collaboration with DailyRounds
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Subscribe To Our Newsletter & Stay Updated
